CDKN2A and astrocytoma (excluding glioblastoma): Similarly, our method could aid in classifying CDKN2A/B-homozygous loss negative samples when proven on a larger cohort, and since loss of CDKN2A/B in IDH mutant astrocytoma is the principal biomarker for poor prognosis, we propose DMS’ potential for its rapid identification of patients with poorer prognosis, hence amenable to undergo GTR.